Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators

A compound having Formula I, its individual enantiomers, its individual diastereoisomers, its individual isomers, its individual tautomers or a pharmaceutically acceptable salt thereof

• wherein:
• represents a single
• or a double bond
• A is substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted C5-8 cycloalkyl, substituted or unsubstituted C5-8 cycloalkenyl, or hydrogen;
• R2 is hydrogen, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R8, NR9R10 or hydroxyl;
• R3 is hydrogen, halogen, substituted or unsubstituted C1-3 alkyl, C(O)R8 or hydroxyl;
• R4 is OPO3H2, carboxylic acid, PO3H2, substituted or unsubstituted C1-6 alkyl, —S(O)2H, —P(O)MeOH, —P(O)(H)OH or OR11;
• R5 is H, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R8, NR9R10 or hydroxyl;
• R6 is H, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R8, NR9R10 or hydroxyl;
• R7 is H, halogen, —OC1-3 alkyl, substituted or unsubstituted C1-3 alkyl, CN, C(O)R8, NR9R10 or hydroxyl;
• R8 is H, OR11 or substituted or unsubstituted C1-3 alkyl;
• R9 is H or substituted or unsubstituted C1-3 alkyl;
• R10 is H or substituted or unsubstituted C1-3 alkyl;
• R11 is H or substituted or unsubstituted C1-3 alkyl;
• L1 is O, S, NH or CHR12;
• L2 is O, S, NH or CHR13;
• R12 is H or substituted or unsubstituted C1-3 alkyl;
• R13 is H or substituted or unsubstituted C1-3 alkyl;
• a is 1;
• b is 0, 1, 2 or 3;
• c is 0, 1, 2, 3 or 4;
• d is 1, 2, 3 or 4;
• represents